Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study-Reference-Cited by-同舟云学术

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

Published:2023-12 Issue:6 Volume:8 Page:102041
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Joris S.,Denys H.,Collignon J.,Rasschaert M.,T’Kint de Roodenbeke D.,Duhoux F.P.,Canon J.-L.,Tejpar S.,Mebis J.,Decoster L.,Aftimos P.,De Grève J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Comprehensive characterization of cancer driver genes and mutations;Bailey;Cell,2018

2. PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment;Thouvenin;ESMO Open,2022

3. Somatic variants in DNA damage response genes in ovarian cancer patients using whole-exome sequencing;Lopacinska-Joergensen;Anticancer Res,2023

4. Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients;Dalmasso;Int J Mol Sci,2022

5. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial;DiSilvestro;J Clin Oncol,2023

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity;JNCI Cancer Spectrum;2024-07-01

3. Navigating Change in Tumor Naming: Exploring the Complexities and Considerations of Shifting Toward Molecular Classifications;Journal of Clinical Oncology;2024-06-27

4. Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?;Cells;2024-06-20

5. SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells;2024-06-17